Clinical Trial Update: Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study evaluating CC-292 in combination with Rituximab in patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CC-292
• Rituximab (rituximab)

Snippet

Sponsor: Celgene Corporation | Conditions: Leukemia Lymphocytic Chronic B-Cell | Phase 1 | Status: COMPLETED